Clinical Research determines the safety effectiveness of new medication. The ambit of Clinical Research at Medica Superspecialty Hospital will cover Phase II / III/IV studies with different indication like Metastatic Breast Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, COVID and POST COVID indication, Coronary Bifurcation Lesion, Nephrological studies. MEDICA is well equipped with the highest standards for Clinical research purposes with high quality local laboratories facilities.
Medica encourages Senior Consultants, Junior Consultants, DNB staff to undertake the research activities in their areas of expertise.
All Clinical Studies will follow protocol compliant with International Good Clinical Practices, New Drug CT Rules 2019.Patient Safety & well-being is the main focal point of all clinical Studies. All study proposals will be reviewed by Clinical Research Ethics Committee & the periodical study status reviewed by according to the Standard Operating Procedure (SOP).
Metastatic breast cancer is essentially stage IV breast cancer. It’s also referred to as advanced breast cancer. For women with stage IV breast cancer, systemic (drug) therapies are the main treatments. These may include: Hormone therapy, Chemotherapy, Immunotherapy etc., Medica is conducting some Phase III clinical trials with this indication of patients.
Lung cancer is the leading cause of cancer related mortality world-wide and amongst males in India. About 85% of lung cancers are non-small cell lung cancers (NSCLC). Stage III disease comprises approximately 30% of the NSCLC diagnosis. It comprises a heterogeneous patient population with 2 subsets: Stage IIIA and IIIB. The current standard-of-care for patients with locally advanced, unresectable, NSCLC is concurrent chemoradiation administered with a curative intent. Here Medica is creating the opportunity to participate in the clinical trial with this indication.
Ovarian Cancer is the third leading Cancer among women next to cervical and breast cancer. In India incidence of ovarian cancer as reported in various population based registries ranges in between 1.7-15.2. The prognosis of ovarian cancer is worst among all the gynecological malignancies with the 5 year survival rate. Now Medica is doing Phase IV study with this indication.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. During this pandemic situation the dedicated research team of Medica provides their effort for clinical trials also. Here Phases II, III, IV studies are going on.